Effect of statins in stroke prevention

Current Opinion in Lipidology

Volumn 16, Issue 6, 2005, Pages 614-618

  Amarenco, Pierre ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Cholesterol; Prevention; Statins; Stroke

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ARTERY INTIMA PROLIFERATION; BLOOD VESSEL WALL; BRAIN INFARCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 29444456377     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000194127.99968.ca     Document Type: Review

References (26)

1. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653.
2. Goldstein LB, Amarenco P, Bogousslavsky J, et al. Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out. Cerebrovasc Dis 2004; 18:1-2.
3. Iso H, Jacobs DR, Wentworth D, et al. For the MRFIT Research Group. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320:904-910.
4. Ebrahim S, Sung J, Song Y-M, et al. Serum cholesterol, haemorrhagic and ischaemic stroke: the Korean National Health Service prospective cohort study. Cerebrovasc Dis 2005; 19 (Suppl 2):
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
6. Amarenco P, Labreuche J, Lavallée P, Touboul P-J. Statin in stroke prevention and carotid atherosclerosis : systematic review and meta-analysis. Stroke 2004; 35:2902-2909. The meta-analysis of over 90 000 patients included in statin trials shows that overall stroke risk reduction is 22% without any heterogeneity between trials, and that the lower the LDL reduction the greater the stroke risk reduction.
7. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
8. LaRosa JC, Grundy SM, Waters DD, et al. For the Treating to New Target (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
9. Amarenco P. Hypercholesterolemia, lipid lowering agent and the risk of brain infarction. Neurology 2001; 57 (Suppl 2):S35-S44.
10. Amarenco P, Lavallée P, Touboul P-J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004; 3:271-278.
11. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA 2001; 285:1711-1718.
12. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction. Circulation 2002; 106:1690-1695.
13. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on the blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34:1281-1286.
14. Cook NR, Cohen J, Hekbert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155:701-709.
15. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343:317-326.
16. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations: a multicentre randomized controlled trial. Lancet 2003; 361:1149-1158.
17. Crisby M, Nordin-Fredricksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Implications for plaque stabilization. Circulation 2001; 103:926-933.
18. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995; 332:512-521.
19. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279:1643-1650.
20. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712-1719.
21. Zureik M, Touboul PJ, Bonithon-Kopp C, et al. Cross-sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intima-media thickness in a general population: the EVA study. Stroke 1999; 30:550-555.
22. Heart Protection Study Collaborative Group. Effect of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757-767. This study demonstrated that after a stroke event, prescription of simvastatin 4.3 years after the event significantly reduced the 5-year major coronary event rate but not recurrent stroke rate.
23. Patel A, Woodward M, Campbell DJ, et al. Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. Eur Heart J 2005; 26:1910-1915. This case-control study nested in the PROGRESS cohort (with over 6000 patients included in a placebo-controlled trial aiming at reducing blood pressure by 10/04 mmHg in mean) showed that total cholesterol was significantly higher in patients who have had a major coronary event during the follow-up compared with patients who have had no such events but failed to show a higher total cholesterol level in patients who have had a recurrent stroke.
24. Amarenco P. Lipid lowering and recurrent stroke: another stroke paradox? Eur Heart J 2005; 26:1818-1819.
25. Shepherd J, Blauw GJ, Murphy MB, et al. On behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630.
26. The SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL). Cerebrovasc Dis 2003; 16:389-395.